Partnerships you can build on

Investor resources

Holburn Biomedical Corporation is a contract research organization that provides customized research and development solutions for the pharmaceutical, biotechnology and diagnostic industries.

Operating at the interface between academic research and commercial scientific development, we provide expert solutions in biomarker development, pathology, physiology, immunology and gastrointestinal diseases.

Our mission is to provide innovative research, integrated solutions and comprehensive consultation, enabling our clients to realize their goals.

 

Product pipeline

Holburn is committed to our strategic vision of growth and profitability with a focus on novel biomedical R&D programs in the healthcare diagnostic and therapeutic spheres. We conduct leading-edge studies in pathology and gastrointestinal physiology, building an intellectual property (IP) inventory.

  • Cannabinoids

    Holburn is formulating, testing and manufacturing cannabinoid-based tablets to act as anti-inflammatory substances, particularly for patients with irritable bowel syndrome (IBS).

  • Companion diagnostics

    Companion diagnostics encompasses the process of screening patients for a particular biomolecular marker, which can then be used to determine the likelihood of successful treatment with a particular therapeutic compound. This may enable clinicians to recognize patients with different types of diseases ranging from cancer to functional bowel disorders.

  • Diagnostic pathology products

    Holburn is developing novel stable reagents for histological methods, raising novel antibodies for use in research and diagnostic pathology, designing novel probes for the identification of new drug targets and generating control materials.

 

With over 25 years of experience in the healthcare diagnostics and therapeutics arenas, we know what it takes to turn a great idea into a successful product.

Over 25 years of discovery and innovation

Holburn has been a key player in the healthcare diagnostics and therapeutics arena for more than 25 years. We have built many successful partnerships and performed contract research work in the field of irritable bowel syndrome (IBS) and visceral hypersensitivity for GlaxoSmithKline (GSK), Novartis, Johnson and Johnson (J&J; both Beerse and Springhouse divisions), Solvay, Movetis, Shire and Lexicon; immunology studies for Sanofi Pasteur (including earlier studies conducted for Connaught), Ikaria, Shire and Luitpold Pharma (Luitpold); molecular and cellular pathology for Dynacare (then Gamma-Dynacare) and Keytruda (Merck); and in the pathology test and equipment development arena for Sakura Finetek (Sakura), Agilent (Dako), Cytochroma, Cytokinetics and Panacea Global.

Want to know more about Holburn?

Investor FAQs

  • Holburn’s head office is located in Bowmanville, Ontario, one hour east of Toronto.

  • Holburn Biomedical Corporation was incorporated in 1995 in Bowmanville, Ontario, Canada.

  • Holburn is a privately owned company. At this time there are no public shares.

  • Our fiscal year runs from September 1st through August 31st.

  • You can view our leadership team by visiting the Leadership section of our website.

  • You can contact Investor Relations via email at info@holburn.com for questions or requests.

The future of healthcare diagnostics & therapeutics

From early diagnosis to tailored treatment, in the future of healthcare diagnostics and therapeutics, anything is possible.

Would you like more information about investor or partnership opportunities?